| Subjects | Asthma-related | Cardiac-related | All-cause | ||||
| SAEs | DAEs | SAEs | DAEs | SAEs | DAEs | ||
| Formoterol-randomised patients# | 67 380 | 463 (0.7) | 534 (0.8) | 129 (0.2) | 197 (0.3) | 1865 (2.8) | 1543(2.3) |
| Salmeterol-randomised patients | 4170 | 38 (0.9) | 32 (0.8) | 12 (0.3) | 4 (0.1) | 151 (3.6) | 83 (2.0) |
| CBP-randomised patients | 4394 | 25 (0.6) | 7 (0.2) | 3 (0.1) | 7 (0.2) | 97 (2.2) | 34 (0.8) |
| Non-LABA-randomised patients | 18 740 | 204 (1.1) | 291 (1.6) | 45 (0.2) | 37 (0.2) | 565 (3.0) | 523 (2.8) |
| Total# | 94 683 | 730 (0.8) | 864 (0.9) | 189 (0.2) | 245 (0.3) | 2678 (2.8) | 2183 (2.3) |
Data are presented as n or n (%). CBP: current best practice; LABA: long-acting β-agonist. #: DAEs were not collected in three trials, reducing n for formoterol to 65 774 and n for total to 93 077 with respect to DAEs.